Program

Event's Program

Opening:Organizing Committee
08.30-08.40
Session 1: Antitumor Immunity and Immunomodulation in the tumor microenvironment (part I)

Chairs: C.N. Baxevanis (GR), J. Wischhusen (DE)

  • Viktor Umansky
Conversion of monocytes into myeloid-derived suppressor cells in cancer
08.40-09.00
Viktor Umansky
  • Barbara Seliger
Ying and yang of extracellular matrix proteins in tumor development and immune surveillance: novel therapeutic targets?
09.00-09.20
Barbara Seliger
Prof. Dr., Martin-Luther-Universität Halle-Wittenberg Institut für Medizinische Immunologie
Discussion
09.20-09.40
Coffee Break
09.40-10.00
Session 2: Antitumor Immunity and Immunomodulation in the tumor microenvironment (part II)

Chairs: J. Wischhusen (DE), T. Frisan (SE)

  • Anastasia Xagara
Pre-existing immunity in non-small cell lung cancer
10.00-10.20
Anastasia Xagara
Postdoctoral Researcher at Laboratory of Oncology, Medical School of Thessaly, Larisa
  • Vincenzo Bronte
Immunosuppressive environment in pancreatic cancer
10.20-10.40
Vincenzo Bronte
  • Daniel Öhlund
Modulating the tumor-microenvironment in pancreatic cancer
10.40-11.00
Daniel Öhlund
M.D, Ph.D., Assistant Professor and Consultant Oncologist Wallenberg Molecular Medicine Fellow
Discussion
11.00-11.20
Session 3: Immunomodulation of microbiota

Chairs: S. Karagianni (UK), A. Iliopoulos (GR)

  • Teresa Frisan
Dysfunctional T lymphocytes identified by spatial analysis in the microenvironment of Pancreatic Ductal Adenocarcinoma
11.20-11.40
Teresa Frisan
PhD, Professor in Cell and Molecular Biology at Umeå University
  • Océane CB Martin
Microbiota-gut-brain axis in glioblastoma development
11.40-12.00
Océane CB Martin
Associate Professor Université de Bordeaux
Discussion
12.00-12.20
Oral presentations
12.20-14.00

1. HIGH-DIMENSIONAL CYTOF ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN MGUS, SMOLDERING MM, AND MM - N. Paschalidis
2. EXPLORING TCR REPERTOIRE AND IMMUNE-RELATED GENES AS POTENTIAL BIOMARKERS IN HEAD AND NECK CANCER - P. Batsaki
3. IDENTIFICATION OF A NOVEL IMMUNE-GENE SIGNATURE WITH PROGNOSTIC VALUE IN PATIENTS WITH HEAD AND NECK CANCER - P. Batsaki
4. TRANSFRMING GROWTH FACTOR BETA IMPACTS NATURAL KILLER CELL PHENOTYPE AND FUNCTIONALITY - G. Isvoranu
5. RARE CASE OF SIGNET RING CELL ADENOCARCINOMA OF THE BLADDER IN A YOUNG WOMAN - C. Belantis
6. HLOROQUINE -MEDIATED INDUCTION OF HLA-CLASS-I IN LUNG CANCER CELL LINES: IMPLICATIONS IN ANTI-PD-L1 IMMUNOTHERAPY - E. Xanthopoulou
7. RECLINICAL EVALUATION OF THE ANTI-CANCER ACTIVITY OF OLE-16, A NEW SYNTHETIC ANALOG OF OLEUROPEIN - C. Knai
8. INVESTIGATION OF CELLULAR SENESCENCE IN THE BONE MARROW DURING MULTIPLE MYELOMA PROGRESSION - N. Poulis

Light Lunch
14.00-15.00
Session 4: Novel anticancer therapies (Part I)

Chairs: C.N. Baxevanis (GR), V. Umansky (DE)

  • Alejandro Madrigal
CAR-T cell and beyond for the treatment of malignant disorders and other conditions.
15.00-15.20
Alejandro Madrigal
  • Jörg Wischhusen
Targeting onco-fetal immune tolerance mechanisms for cancer immunotherapy
15.20-15.40
Jörg Wischhusen
Professor of Experimental Tumor Immunology University of Würzburg School of Medicine Department of Gynecology and Obstetrics
  • Nadia Mensali
Immunotherapeutic strategies for solid tumours
15.40-16.00
Nadia Mensali
Researcher; PhD, Msc
Discussion
16.00-16.20
Coffee Break
16.20-17.00
Keynote lecture

Chairs: M. Koukourakis (GR), C.N. Baxevanis (GR)

  • Gosse Adema
Radiotherapy induced cGAS re-localization and immune signature in HNSCC as a predictor of treatment efficacy
17.00-17.30
Gosse Adema
Educational lecture

E. Saloustros (GR), V. Georgoulias (GR)

  • Oraianthi Fiste
Novel therapeutic approaches in gynecological cancer
17.30-18.00
Oraianthi Fiste
MD, MSc, Medical Oncologist, Sub-Investigator of Clinical Trials Bureau, MD, MSc, Medical Oncologist, Sub-Investigator of Clinical Trials Bureau, 3rd Dept of Internal Medicine at National and Kapodistrian University, Thoracic General Hospital of Athens "I SOTIRIA", Athens Greece
Coffee Break
18.00-18.30
Educational lectures

Chairs: C.Ν. Βaxevanis (GR), S. Karagiannis (UK)

  • Cecile Gouttefangeas
Novel approaches for glioblastoma vaccination
18.30-19.00
Cecile Gouttefangeas
Group leader at the Institute for Cell Biology, Department of Immunology, Tübingen.
  • Federica Cavallo
The cystine/glutamate antiporter in breast cancer: an xCTing target
19.00-19.30
Federica Cavallo
Full Professor of Immunology Department of Molecular Biotechnology and Health Sciences
Interactive session with the Speakers from Day 1
19.30-21.30
Session 5: Cancer Biomarkers (part I)

Chairs: S. Karagiannis (UK), N. Mensali (NO)

  • Antonios Chatzigeorgiou
Novel insight in tumor microenvironment in liver cancer A.
08.40-09.00
Antonios Chatzigeorgiou
Associate Professor of Experimental and Clinical Physiology Department of Physiology, School of Medicine, National and Kapodistrian University of Athens,
  • Noel de Miranda
Charting the Cancer Battlefield: Unraveling Tumor Microenvironments and Immunotherapy Dynamics
09.00-09.20
Noel de Miranda
  • Ioannis S. Pateras
Novel immune-based biomarkers in common solid tumors
09.20-09.40
Ioannis S. Pateras
Discussion
09.40-10.00
Coffee Break
10.00-10.30
Session 6: Novel Anticancer therapies (part II)

Chairs: S. Karagiannis (UK), N. Mensali (NO)

  • Panagiotis Verginis
Blood immunomap to predict immunotherapy responses
10.30-10.50
Panagiotis Verginis
IMBB Group Leader (Associate Professor, Medical School, Univ. of Crete)
    ERAP1 as a regulator of the immunopeptidome, proteome and ER homeostasis of cancer cells
    10.50-11.10
    • Sophia Karagiannis
    Antibody-drug conjugates (ADCs) for cancer therapy designed through the study of the tumour microenvironment
    11.10-11.30
    Sophia Karagiannis
    Professor of Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London
    Discussion
    11.30-11.50
    Oral presentations
    11.50-13.00

    9. DEVELOPMENT OF AN INNOVATIVE HYDROGEL PRINTING HEAD FOR PRINTING OSTEOCHONDRAL STRUCTURES - V. Fanidis
    10. EO2401, A NOVEL IMMUNOTHERAPY, PLUS NIVOLUMAB INDUCES A STRONG IMMUNE RESPONSE IN RECURRENT GLIOBLASTOMA - A. Maia Santos Leite
    11. ALTERATIONS IN MINIMAL RESIDUAL DISEASE STATUS MODIFIES THE INITIAL PROGNOSTICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS - I.V. Kostopoulos
    12. COMPREHENSIVE ANALYSIS OF DIFFERENT CIRCULATED T-CELL SUBTYPES IN PDAC PATIENTS - K. Vasilieva
    13. CELLULAR IMMUNIOTHERAPY:A NEW CHALLENGE IN AN ALREADY PROMISING FIELD - K. Folinas
    14. MECHANISMS OF THE PD-1/PD-L1 PATHWAY IN IMMUNE EVASION OF HNSCC - E. Litsou

    Light Lunch
    13.00-14.00
    Session 7: Cancer biomarkers (part II)

    Chairs: F. Koinis (GR) G. Pawelec (DE)

    • Maria Goulielmaki
    The biomarker utility of T-cells in NSCLC
    14.00-14.20
    Maria Goulielmaki
    Postdoctoral Researcher at Cancer Immunology and Immunotherapy Center, Athens
    • Alexios Matikas
    Dissecting the tumor microenvironment in early breast cancer: clinical implications and novel insights
    14.20-14.40
    Alexios Matikas
    • Gilles Marodon
    Targeting co stimulatory molecules for cancer immunotherapy: good or bad idea?
    14.40-15.00
    Gilles Marodon
    • Apostolos Klinakis
    Epigenetic regulation in cancer
    15.00-15.20
    Apostolos Klinakis
    PhD, Investigator - Professor Level
    Discussion
    15.20-15.40
    Session 8: Melanoma: past – present – future in immunotherapy

    Chairs: Η. Gogas (GR)

    • Graham Peter Pawelec
    Cytomegalovirus and immunosenescence: impact on melanoma immunotherapy
    15.40-16.00
    Graham Peter Pawelec
    Professor of Experimental Immunology, Center of Medical Research, Department of Immunology, University of Tuebingen
    • Apostolos Laskarakis
    Advances in the management of early stage melanoma- the role of Immunotherapy
    16.00-16.20
    Apostolos Laskarakis
    Director of Oncology Department at Athens Medical Group
    Sponsored lecture
    16.20-16.50
    Discussion
    16.50-17.00
    Coffee break
    17.00-17.15
    Session 9: Non-small cell lung cancer: past – present – future in immunotherapy

    Chairs: K. Tsapakidis (GR), V. Georgoulias (GR)

    Sponsored lecture
    17.15-17.45
    Sponsored lecture
    17.45-18.15
    Sponsored lecture
    18.15-18.45
    • Dionysios Papadatos - Pastos
    State of the art of immunotherapy in the first line setting in NSCLC
    18.45-19.15
    Dionysios Papadatos - Pastos
    Discussion
    19.15-19.30
    Educational lecture
    19.30-20.00

    Chair. A. Kotsakis (GR)
    New therapeutic approached in SCLC - K. Leventakos (US)

    Coffee Break
    20.00-20.15
    Interactive session with the Speakers from Day 2
    20.15-21.30
    Session 10: Immunotherapies alone or in combination with other therapies

    Chairs: A. Kotsakis (GR)

    • Petros Tsantoulis
    Immunotherapy in urothelial carcinomas
    08.40-09.00
    Petros Tsantoulis
    • Ioannis Koukourakis
    Combining radiotherapy and immunotherapy
    09.00-09.20
    Ioannis Koukourakis
    Discussion
    09.20-09.30
    Sponsored Lecture
    09.30-10.00
    Educational lecture

    Chairs: S. Karagianni (UK), A. Klinakis (GR)

    • Sofia Tsoka
    Bio-informatic analysis in cancer immunology and immunotherapy
    10.00-10.30
    Sofia Tsoka
    Reader in Bioinformatics, King's College London
    Abstracts Awards: Organizing Committee
    10.30-10.40
    Interactive session with the Speakers
    10.40-11.40
    Concluding remarks
    11.40-12.00
    Friday, 06 December 2024
    Session 5: Melanoma: past – present – future in immunotherapy
    • Georgios Lazarides
    Sponsored lecture BMS - 10yrs of IO evolution in Melanoma
    Georgios Lazarides
    MD, PhD, Medical Oncologist
    Session 9: Non-small cell lung cancer: past – present – future in immunotherapy
    17.15-17.45
    • Giannis Mountzios
    Sponsored lecture – BMS : New horizons in 1L metastastatic NSCLC with dual IO
    17.45-18.15
    Giannis Mountzios
    MSc, PhD, Medical Oncologist, Director, 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center, Athens, Greece
    • Alessio Cortellini
    Sponsored lecture – Astra Zeneca- Early-Stage NSCLC and Immunotherapy: Unraveling Mechanistic Pathways for Improved Outcomes
    18.15-18.45
    Alessio Cortellini
    Professor, Campus Bio-Medico, Rome
    • Thorsten Füreder
    Sponsored lecture - MSD - Advances in the treatment algorithm of resectable NSCLC: improving overall survival with immunotherapy
    Thorsten Füreder
    Professor, Medical University Vienna, Austria
    Saturday, 07 December 2024
    • Maria Avgoustidou
    Sponsored Lecture Astellas - The value of the Claudin 18.2 biomarker for the management of Gastric and Gastro-esophageal Junction Carcinomas
    09.30-10.00
    Maria Avgoustidou
    MD, ehem.OA, FA, German Board certified oncologist/hematologist specialized in Palliative Care